Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Paul D. Olivo in
Google Scholar
PubMed
Search for other papers by Yie-Hwa Chang in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
) cells expressing a chimeric human TSH-R. In addition, CHO cells expressing the wild-type (WT) TSH-R and a cAMP-responsive luciferase reporter were utilized to measure TSAb [ 28 ] and TBAb [ 29 ]. These bioassays are based on the transcription of a
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Paul D. Olivo in
Google Scholar
PubMed
Search for other papers by Angelica Unterrainer in
Google Scholar
PubMed
Search for other papers by Jochem König in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by Artur Bossowski in
Google Scholar
PubMed
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
performance of TSHR Ab immunoassays are available, we aimed to measure the lowest possible Ab concentration in several immunoassays and to compare the performance of ELISA and automated assays. FDA-cleared and/or validated functional cell-based bioassays for
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
for measuring the biological activity of molecules and this has been specifically and successfully applied to TSHR-Ab [ 7 ]. TSHR bioassays are functional cell-based tests that directly assess the bioactive immunoglobulins having either stimulating or
Search for other papers by Tanja Diana in
Google Scholar
PubMed
Search for other papers by Hans-Peter Holthoff in
Google Scholar
PubMed
Search for other papers by Julia Fassbender in
Google Scholar
PubMed
Search for other papers by Christian Wüster in
Google Scholar
PubMed
Search for other papers by Michael Kanitz in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Martin Ungerer in
Google Scholar
PubMed
and thyroid-related antibodies. Bioassay for Blocking TSHR Antibodies Levels of serum TSHR-blocking antibodies (TBAb) were measured according to the manufacturer’s (Quidel, San Diego, USA) instructions for the CE-marked cell-based bioassay [ 27
Search for other papers by Naohiro Araki in
Google Scholar
PubMed
Search for other papers by Mitsuru Iida in
Google Scholar
PubMed
Search for other papers by Nobuyuki Amino in
Google Scholar
PubMed
Search for other papers by Shinji Morita in
Google Scholar
PubMed
Search for other papers by Akane Ide in
Google Scholar
PubMed
Search for other papers by Eijun Nishihara in
Google Scholar
PubMed
Search for other papers by Mitsuru Ito in
Google Scholar
PubMed
Search for other papers by Jun Saito in
Google Scholar
PubMed
Search for other papers by Tetsuo Nishikawa in
Google Scholar
PubMed
Search for other papers by Kiyonori Katsuragi in
Google Scholar
PubMed
Search for other papers by Akira Miyauchi in
Google Scholar
PubMed
TSBAb depend on cell-based assays using various cells such as porcine primary cells, human thyroid cells and Fischer rat thyroid cell line-5 (FRTL-5), combined with the measurement of cyclic adenosine monophosphate (cAMP) released from the cells
Search for other papers by Isabelle Clinckspoor in
Google Scholar
PubMed
Search for other papers by Anne-Catherine Gérard in
Google Scholar
PubMed
Search for other papers by Jacqueline Van Sande in
Google Scholar
PubMed
Search for other papers by Marie-Christine Many in
Google Scholar
PubMed
Search for other papers by Lieve Verlinden in
Google Scholar
PubMed
Search for other papers by Roger Bouillon in
Google Scholar
PubMed
Search for other papers by Geert Carmeliet in
Google Scholar
PubMed
Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium
Search for other papers by Chantal Mathieu in
Google Scholar
PubMed
Search for other papers by Annemieke Verstuyf in
Google Scholar
PubMed
Department of Endocrinology, University Hospitals Leuven, Leuven, Belgium
Search for other papers by Brigitte Decallonne in
Google Scholar
PubMed
washed three times and the counts were recorded in a gamma counter. Serum TSH was evaluated by bioassay using a line of Chinese hamster ovary cells (CHO-K1) stably transfected with human TSH receptor cDNA, as previously described [ 30 ]. Five to eleven
Search for other papers by Fabio Maino in
Google Scholar
PubMed
Search for other papers by Cristina Dalmiglio in
Google Scholar
PubMed
Search for other papers by Nicoletta Benenati in
Google Scholar
PubMed
Search for other papers by Michele Campanile in
Google Scholar
PubMed
Search for other papers by Tania Pilli in
Google Scholar
PubMed
Search for other papers by Raffaella Forleo in
Google Scholar
PubMed
Search for other papers by Lucia Brilli in
Google Scholar
PubMed
Search for other papers by Cristina Ciuoli in
Google Scholar
PubMed
Search for other papers by Silvia Cantara in
Google Scholar
PubMed
Search for other papers by Marco Capezzone in
Google Scholar
PubMed
Search for other papers by Alessandra Cartocci in
Google Scholar
PubMed
Search for other papers by Furio Pacini in
Google Scholar
PubMed
Search for other papers by Maria Grazia Castagna in
Google Scholar
PubMed
with a nodular thyroid, the measurement of basal serum CT levels has been proposed as a systematic screening method for MTC [ 2 , 3 ]. The routine measurement of CT in patients with thyroid nodules can be useful in the early diagnosis of MTC and C-cell
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
Search for other papers by Luigi Bartalena in
Google Scholar
PubMed
Search for other papers by Lazlo Hegedüs in
Google Scholar
PubMed
Search for other papers by Laurence Leenhardt in
Google Scholar
PubMed
Search for other papers by Kris Poppe in
Google Scholar
PubMed
Search for other papers by Simon H. Pearce in
Google Scholar
PubMed
-R-Ab concentration measured with second- and third-generation binding assays were 97 and 98%, respectively [ 25 ]. In contrast, the highly sensitive cell-based bioassays [ 26 - 33 ] exclusively differentiate between the TSH-R-stimulating Ab (TSAb) and TSH
Search for other papers by Sandrine Donadio-Andréi in
Google Scholar
PubMed
CARMEN-INSERM U1060, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux, Oullins
Société Française de Médecine Nucléaire, Groupe de Biologie Spécialisée, Centre Antoine Béclère, Paris
Search for other papers by Karim Chikh in
Google Scholar
PubMed
Search for other papers by Christine Heuclin in
Google Scholar
PubMed
Search for other papers by Elisabetta Kuczewski in
Google Scholar
PubMed
CARMEN-INSERM U1060, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux, Oullins
Société Française de Médecine Nucléaire, Groupe de Biologie Spécialisée, Centre Antoine Béclère, Paris
Search for other papers by Anne Charrié in
Google Scholar
PubMed
Laboratoire du Service de Médecine Nucléaire, Centre Hospitalier de Chambéry, Chambéry
Pôle de Biologie, Centre Hospitalier et Universitaire de Grenoble
UMR-S INSERM 1037, Grenoble, France
Search for other papers by Anne-Sophie Gauchez in
Google Scholar
PubMed
Search for other papers by Catherine Ronin in
Google Scholar
PubMed
-Aldrich), pH 7.4. Cyclic AMP released from the cells was measured by RIA (Immunotech, Marseille, France). The negative sera of pooled TSH-receptor antibodies (normal sera) were used to measure cAMP basal production. Results were expressed as the ratio of
Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
DON [ 63 ]. Based on the latest evidence, the EUGOGO recommends that RTX be considered as one of the second-line treatment options after failure of IVGC, but it should not be used in patients with impending DON or long duration of disease [ 2 ]. B cell